A randomized double-blind placebo-controlled clinical trial of once-daily inhaled molgramostim nebulizer solution in adult subjects with autoimmune pulmonary alveolar proteinosis (aPAP)

A randomized double-blind placebo-controlled clinical trial of once-daily inhaled molgramostim nebulizer solution in adult subjects with autoimmune pulmonary alveolar proteinosis (aPAP)
Recruiting
18 years - 99 years
All
Phase 3
160 participants needed
1 Location

Brief description of study

The present confirmatory phase 3 trial will be conducted to further investigate the efficacy and safety of molgramostim in subjects with aPAP. Investigating how molgramostim improves lung pathology, pathophysiology, and health status in subjects with aPAP in a dose- frequency dependent fashion.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Pulmonary Alveolar Proteinosis,Autoimmune Diseases,Lung Diseases,Respiratory Tract Diseases,Immune System Diseases
  • Age: 18 years - 99 years
  • Gender: All

Participant must be ≥18 years of age ,

Diagnosis of autoimmune PAP.

Updated on 04 Aug 2024. Study ID: 848998

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center